FI60701C - Foerfarande foer framstaellning av terapeutiskt anvaendbar dihydrocyklosporin c - Google Patents

Foerfarande foer framstaellning av terapeutiskt anvaendbar dihydrocyklosporin c Download PDF

Info

Publication number: FI60701C
Authority: FI; Finland
Prior art keywords: chj; therapeutic; dihydrocyclosporin; cyclosporin; iii
Prior art date: 1975-11-04

Application number

FI763049A

Other languages

English (en)

Finnish (fi)

Other versions

FI763049A7 (fr

FI60701B (fi

Inventor

Artur Rueegger

Max Kuhn

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-11-04

Filing date

1976-10-26

Publication date

1982-03-10

1976-10-26 Application filed by Sandoz Ag filed Critical Sandoz Ag

1977-05-05 Publication of FI763049A7 publication Critical patent/FI763049A7/fi

1980-06-30 Priority to FI802084A priority Critical patent/FI60718C/fi

1981-11-30 Application granted granted Critical

1981-11-30 Publication of FI60701B publication Critical patent/FI60701B/fi

1982-03-10 Publication of FI60701C publication Critical patent/FI60701C/fi

Links

108010040786 dihydrocyclosporin C Proteins 0.000 title claims description 14
230000001225 therapeutic effect Effects 0.000 title 3
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 claims description 12
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 claims description 12
108010019248 cyclosporin C Proteins 0.000 claims description 12
238000000034 method Methods 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 5
238000005984 hydrogenation reaction Methods 0.000 claims description 4
QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 claims 1
102100030500 Heparin cofactor 2 Human genes 0.000 claims 1
101710153650 Heparin cofactor 2 Proteins 0.000 claims 1
101000941448 Lasioglossum laticeps Lasioglossin-2 Proteins 0.000 claims 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 9
229930105110 Cyclosporin A Natural products 0.000 description 8
108010036949 Cyclosporine Proteins 0.000 description 8
229960001265 ciclosporin Drugs 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
UCOQITKXMNKTKF-MXGZYYNMSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28,30-decamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C)NC1=O UCOQITKXMNKTKF-MXGZYYNMSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
229930182912 cyclosporin Natural products 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
101710154606 Hemagglutinin Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
241000123975 Trichoderma polysporum Species 0.000 description 2
DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000000203 mixture Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
101000765308 Aspergillus niger N-(5'-phosphoribosyl)anthranilate isomerase Proteins 0.000 description 1
241000875119 Cylindrocarpon lucidum Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241000364057 Peoria Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
-1 aliphatic alcohols Chemical class 0.000 description 1
230000002022 anti-cellular effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
150000002940 palladium Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/885—Trichoderma
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Botany (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FI763049A 1975-11-04 1976-10-26 Foerfarande foer framstaellning av terapeutiskt anvaendbar dihydrocyklosporin c FI60701C (fi)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
FI802084A FI60718C (fi)	1975-11-04	1980-06-30	En ny ringpeptid cyklosporin c anvaendbar som mellanprodukt vid framstaellning av dihydrocyklosporin c och ett foerfarande foer dess framstaellning

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH1419575		1975-11-04
CH1419575A CH614931A5 (fr)	1975-11-04	1975-11-04

Publications (3)

Publication Number	Publication Date
FI763049A7 FI763049A7 (fr)	1977-05-05
FI60701B FI60701B (fi)	1981-11-30
FI60701C true FI60701C (fi)	1982-03-10

Family

ID=4398730

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI763049A FI60701C (fi)	1975-11-04	1976-10-26	Foerfarande foer framstaellning av terapeutiskt anvaendbar dihydrocyklosporin c

Country Status (23)

Country	Link
US (1)	US4108985A (fr)
JP (2)	JPS5259180A (fr)
AT (1)	AT359642B (fr)
AU (1)	AU513538B2 (fr)
BE (1)	BE847941A (fr)
CA (1)	CA1087609A (fr)
CH (2)	CH614931A5 (fr)
DE (2)	DE2648121C2 (fr)
DK (1)	DK148907C (fr)
ES (1)	ES452942A1 (fr)
FI (1)	FI60701C (fr)
FR (2)	FR2330387A1 (fr)
GB (2)	GB1567202A (fr)
IE (2)	IE44750B1 (fr)
IL (1)	IL50836A (fr)
NL (1)	NL7612026A (fr)
NO (1)	NO763667L (fr)
NZ (1)	NZ182496A (fr)
PH (1)	PH14725A (fr)
PT (1)	PT65791B (fr)
SE (2)	SE432247B (fr)
YU (1)	YU270076A (fr)
ZA (1)	ZA766340B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4210581A (en) *	1975-11-04	1980-07-01	Sandoz Ltd.	Organic compounds
DE2819094A1 (de) *	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
FR2410658A1 (fr) *	1977-11-30	1979-06-29	Science Union & Cie	Nouveau produit biologique d'origine fongique, son obtention et son application a la therapeutique
FI65914C (fi) *	1978-03-07	1984-08-10	Sandoz Ag	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
SE448386B (sv) *	1978-10-18	1987-02-16	Sandoz Ag	Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en) *	1979-03-12	1980-05-06	Merck & Co., Inc.	Antibiotic A43F
JPS5665853A (en) *	1979-11-01	1981-06-03	Sankyo Co Ltd	Mycoplanesin derivative and its preparation
IE54936B1 (en) *	1980-02-14	1990-03-28	Sandoz Ltd	A method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US4396542A (en) *	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US4370266A (en) *	1980-04-07	1983-01-25	Sankyo Company, Limited	Mycoplanecin derivatives and their preparation
EP0056782B1 (fr) *	1981-01-09	1984-08-01	Sandoz Ag	Cyclosporines
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB8422253D0 (en) *	1984-09-04	1984-10-10	Sandoz Ltd	Organic compounds
ATE92501T1 (de) *	1984-10-04	1993-08-15	Sandoz Ag	Monoklonale antikoerper gegen zyklosporine.
US4727035A (en) *	1984-11-14	1988-02-23	Mahoney Walter C	Immunoassay for cyclosporin
US4764503A (en) *	1986-11-19	1988-08-16	Sandoz Ltd.	Novel cyclosporins
US4798823A (en) *	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"
DE3884470T2 (de) *	1987-06-17	1994-03-10	Sandoz Ag	Cyclosporine und deren Benutzung als Arzneimittel.
EP0373260B1 (fr) *	1987-06-22	1994-03-09	Merck & Co. Inc.	Dérivés de cyclosporine avec un acide aminé modifié en position 8
GB8717300D0 (en) *	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
GB8717299D0 (en) *	1987-07-22	1987-08-26	Nat Res Dev	Peptides
US5227467A (en) *	1987-08-03	1993-07-13	Merck & Co., Inc.	Immunosuppressive fluorinated cyclosporin analogs
ATE109970T1 (de) *	1987-09-03	1994-09-15	Univ Georgia Res Found	Cyclosporin-augenmittel.
US4839342A (en) *	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
US5236899A (en) *	1987-11-16	1993-08-17	Merck & Co., Inc.	6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4914188A (en) *	1987-11-16	1990-04-03	Merck & Co., Inc.	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
HU203564B (en) *	1987-12-21	1991-08-28	Sandoz Ag	Process for producing new orthorombos cyclosporin without solvatation
US4943560A (en) *	1988-04-06	1990-07-24	Regents Of The University Of Minnesota	Solvent system for chronic vascular infusion of hydrophobic drugs
US5342625A (en) *	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en) *	1989-02-20	2006-07-25	Novartis Ag	Cyclosporin galenic forms
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
GB8916901D0 (en)	1989-07-24	1989-09-06	Sandoz Ltd	Improvements in or relating to organic compounds
US5122511A (en) *	1990-02-27	1992-06-16	Merck & Co., Inc.	Immunosuppressive cyclosporin analogs with modified amino acids at position-8
WO1992013094A1 (fr) *	1991-01-25	1992-08-06	Fujisawa Pharmaceutical Co., Ltd.	Procede pour produire de la cyclosporine a et/ou c
ES2065273B1 (es) *	1993-05-25	1995-09-16	Biogal Gyogyszergyar	Procedimiento para la purificacion de ciclosporina a.
US5709797A (en) *	1996-06-05	1998-01-20	Poli Industria Chimica S.P.A.	Method of isolating cyclosporins
ATE275963T1 (de)	1997-01-30	2004-10-15	Novartis Pharma Gmbh	Ölfreie pharmazeutische zusammensetzung welche cyclosporin enthält
US6187747B1 (en)	1997-09-08	2001-02-13	Panacea Biotech Limited	Pharmaceutical composition comprising cyclosporin
IN188719B (fr) *	1997-09-08	2002-11-02	Panacea Biotec Ltd
US6008191A (en) *	1997-09-08	1999-12-28	Panacea Biotec Limited	Pharmaceutical compositions containing cyclosporin
US6346511B1 (en)	1997-09-08	2002-02-12	Panacea Biotec Limited	Pharmaceutical composition comprising cyclosporin
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
DE69840586D1 (de)	1997-10-08	2009-04-02	Isotechnika Inc	Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
DE69928938T2 (de)	1998-07-01	2006-08-17	Debiopharm S.A.	Neues cyclosporin mit verbesserter wirkung
CN100334106C (zh) *	2001-10-19	2007-08-29	伊索泰克尼卡股份有限公司	环孢菌素类似物的合成
US7060672B2 (en) *	2001-10-19	2006-06-13	Isotechnika, Inc.	Cyclosporin analog formulations
JP2006524232A (ja)	2003-03-17	2006-10-26	アルバニーモレキュラーリサーチインコーポレーティッド	新規サイクロスポリン
US20060014677A1 (en) *	2004-07-19	2006-01-19	Isotechnika International Inc.	Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
JP2008514701A (ja)	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	シクロスポリンアルキン類似体およびそれらの薬学的使用
US7511013B2 (en)	2004-09-29	2009-03-31	Amr Technology, Inc.	Cyclosporin analogues and their pharmaceutical uses
WO2006041631A2 (fr)	2004-10-06	2006-04-20	Amr Technology, Inc.	Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques
US10137083B2 (en)	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
US11311477B2 (en)	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
US7696166B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20080206287A1 (en) *	2006-09-18	2008-08-28	Reed John C	Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
TW200932240A (en)	2007-10-25	2009-08-01	Astellas Pharma Inc	Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
WO2010088573A1 (fr) *	2009-01-30	2010-08-05	Enanta Pharmaceuticals, Inc.	Analogues de la cyclosporine pour prévenir ou traiter une infection par l'hépatite c
US8481483B2 (en) *	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8685917B2 (en) *	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8349312B2 (en) *	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8623814B2 (en) *	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
CN103153329A (zh)	2010-07-16	2013-06-12	美国科技环球有限公司	新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
WO2012021796A2 (fr)	2010-08-12	2012-02-16	S&T Global, Inc.	Nouveaux dérivés de cyclosporine destinés à la prévention ou au traitement d'une infection virale
US9890198B2 (en)	2010-12-03	2018-02-13	S&T Global Inc.	Cyclosporin derivatives and uses thereof
PL2651965T3 (pl)	2010-12-15	2019-04-30	Contravir Pharmaceuticals Inc	Cząsteczki analogów cyklosporyny modyfikowane w aminokwasach 1 i 3
WO2012145427A1 (fr)	2011-04-18	2012-10-26	The Trustees Of Columbia University In The City Of New York	Méthodes de traitement du cancer à l'aide de cyclosporine et de dérivés de cyclosporine
WO2014085623A1 (fr)	2012-11-28	2014-06-05	Enanta Pharmaceuticals, Inc.	Nouveaux analogues de [n-me-4-hydroxyleucine]-9-cyclosporine
WO2015031381A1 (fr)	2013-08-26	2015-03-05	Enanta Pharmaceuticals, Inc.	Analogues de cyclosporine pour prévenir ou traiter une hépatite c
US9669095B2 (en)	2014-11-03	2017-06-06	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues for preventing or treating hepatitis C infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2455859C2 (de) *	1973-12-06	1983-12-15	Sandoz-Patent-GmbH, 7850 Lörrach	Das Antibiotikum Cyclosporin A (S 7481/F-1), seine Herstellung und Verwendung

1975
- 1975-11-04 CH CH1419575A patent/CH614931A5/xx not_active IP Right Cessation
1976
- 1976-10-23 DE DE2648121A patent/DE2648121C2/de not_active Expired
- 1976-10-23 DE DE2661031A patent/DE2661031C2/de not_active Expired
- 1976-10-25 ZA ZA00766340A patent/ZA766340B/xx unknown
- 1976-10-26 DK DK483176A patent/DK148907C/da not_active IP Right Cessation
- 1976-10-26 FI FI763049A patent/FI60701C/fi not_active IP Right Cessation
- 1976-10-27 US US05/736,106 patent/US4108985A/en not_active Expired - Lifetime
- 1976-10-27 SE SE7611906A patent/SE432247B/xx unknown
- 1976-10-27 NO NO763667A patent/NO763667L/no unknown
- 1976-10-29 NL NL7612026A patent/NL7612026A/xx not_active Application Discontinuation
- 1976-11-02 GB GB19922/79A patent/GB1567202A/en not_active Expired
- 1976-11-02 JP JP51131314A patent/JPS5259180A/ja active Granted
- 1976-11-02 PH PH19079A patent/PH14725A/en unknown
- 1976-11-02 NZ NZ182496A patent/NZ182496A/xx unknown
- 1976-11-02 IE IE2379/81A patent/IE44750B1/en unknown
- 1976-11-02 GB GB45485/76A patent/GB1567201A/en not_active Expired
- 1976-11-02 CA CA264,703A patent/CA1087609A/fr not_active Expired
- 1976-11-02 AU AU19262/76A patent/AU513538B2/en not_active Ceased
- 1976-11-02 IE IE2439/76A patent/IE44749B1/en unknown
- 1976-11-03 PT PT65791A patent/PT65791B/fr unknown
- 1976-11-03 AT AT812276A patent/AT359642B/de not_active IP Right Cessation
- 1976-11-03 ES ES452942A patent/ES452942A1/es not_active Expired
- 1976-11-03 YU YU02700/76A patent/YU270076A/xx unknown
- 1976-11-03 IL IL50836A patent/IL50836A/xx unknown
- 1976-11-03 BE BE172045A patent/BE847941A/fr not_active IP Right Cessation
- 1976-11-04 FR FR7633231A patent/FR2330387A1/fr active Granted
1977
- 1977-04-21 FR FR7711993A patent/FR2338251A1/fr active Granted
1979
- 1979-06-11 CH CH543479A patent/CH619735A5/de not_active IP Right Cessation
1982
- 1982-03-30 SE SE8202039A patent/SE8202039L/sv not_active Application Discontinuation
1986
- 1986-09-11 JP JP61215602A patent/JPS6277399A/ja active Granted

Also Published As

Publication number	Publication date
IE44750L (en)	1977-05-04
FI763049A7 (fr)	1977-05-05
IL50836A0 (en)	1977-01-31
CH614931A5 (fr)	1979-12-28
JPS6210240B2 (fr)	1987-03-05
IE44749B1 (en)	1982-03-24
AT359642B (de)	1980-11-25
DE2648121C2 (de)	1986-05-28
SE8202039L (sv)	1982-03-30
SE432247B (sv)	1984-03-26
ES452942A1 (es)	1978-01-16
JPS6277399A (ja)	1987-04-09
IE44749L (en)	1977-05-04
PT65791A (fr)	1976-12-01
IL50836A (en)	1979-10-31
IE44750B1 (en)	1982-03-24
GB1567201A (en)	1980-05-14
AU1926276A (en)	1978-05-11
FR2330387B1 (fr)	1980-03-14
PH14725A (en)	1981-11-13
DK148907C (da)	1986-04-07
NO763667L (fr)	1977-05-05
US4108985A (en)	1978-08-22
FI60701B (fi)	1981-11-30
DK483176A (da)	1977-05-05
BE847941A (fr)	1977-05-03
FR2338251B1 (fr)	1984-01-13
CA1087609A (fr)	1980-10-14
JPS6253520B2 (fr)	1987-11-10
SE7611906L (sv)	1977-05-05
NL7612026A (nl)	1977-05-06
DE2648121A1 (de)	1977-05-12
YU270076A (en)	1982-05-31
FR2330387A1 (fr)	1977-06-03
FR2338251A1 (fr)	1977-08-12
DK148907B (da)	1985-11-11
GB1567202A (en)	1980-05-14
PT65791B (fr)	1978-07-05
DE2661031C2 (fr)	1988-05-05
AU513538B2 (en)	1980-12-11
JPS5259180A (en)	1977-05-16
ATA812276A (de)	1980-04-15
ZA766340B (en)	1978-06-28
CH619735A5 (fr)	1980-10-15
NZ182496A (en)	1981-12-15

Publication	Publication Date	Title
FI60701C (fi)	1982-03-10	Foerfarande foer framstaellning av terapeutiskt anvaendbar dihydrocyklosporin c
US4210581A (en)	1980-07-01	Organic compounds
CY1286A (en)	1985-07-05	Cyclosporin derivatives their production and pharmaceutical compositions containing them
Chi et al.	1991	Identification of the in vivo metabolites of the antimalarial arteether by thermospray high‐performance liquid chromatography/mass spectrometry
Calcagno et al.	1996	New phytoecdysteroids from roots of Ajuga reptans varieties
Pettit et al.	1998	Antineoplastic agents 397: Isolation and structure of sesterstatins 4 and 5 from hyrtios erecta (the republic of maldives)
Rao et al.	1960	E-73: An antitumor substance. Part I. isolation and characterization1
UENO et al.	1978	Studies on the lupin alkaloids. VII. Isolation and structure of (-)-Δ7-dehydrosophoramine
CN104387396B (zh)	2016-08-24	源于米曲霉的吲哚萜speradine E及应用
CN108558606B (zh)	2020-04-07	一种二倍半萜类化合物peniroquesines及其制备方法和应用
US8586626B2 (en)	2013-11-19	Metabolites of wortmannin analogs and methods of using the same
Michel et al.	1975	NEW AZASTEROIDAL ANTIFUNGAL ANTIBIOTICS FROM GEOTRICHUM FLAVO-BRUNNEUM II. ISOLATION AND CHARACTERIZATION
CA1106303A (fr)	1981-08-04	Cyclosporin c a partir de tolypocladium ou de cylindrocarpon
Goud et al.	2003	Two new bromotyrosine-derived metabolites from the sponge Psammaplysilla purpurea
CN118754892A (zh)	2024-10-11	一种具有抗骨肉瘤活性化合物及其制备方法和应用
CN105218442B (zh)	2017-12-15	一种吡啶酮类生物碱及其制备方法
Clericuzio et al.	2004	Structural characterisation of metabolites from Pholiota spumosa (Basidiomycetes)
Kinoshita et al.	1995	New triterpenes from Trichocereus pachanoi
CN108676013B (zh)	2021-01-01	具有自噬激活活性的黄醇酮类化合物、其制备方法及其制药应用
CN108822119B (zh)	2020-08-28	具有自噬激活活性的红醇酮类化合物、其制备方法及其制药应用
FI60718C (fi)	1982-03-10	En ny ringpeptid cyklosporin c anvaendbar som mellanprodukt vid framstaellning av dihydrocyklosporin c och ett foerfarande foer dess framstaellning
CN115160236B (zh)	2024-01-19	Corallorazines类化合物及其制备方法和应用
CN114920730B (zh)	2024-10-01	一种雷帕霉素开环降解杂质及其制备方法和应用
FI63742B (fi)	1983-04-29	Foerfarande foer framstaellning av terapeutiskt anvaendbart diydrocyklosporin
CN106543193B (zh)	2018-10-16	3-(3-乙酰基-4甲基吡啶)-(Z)-5-亚乙基-8-羟基-3，4，5，6-四氢基-1H-吡喃并[3,4,c]-吡啶-1-酮及其制备方法

Legal Events

Date	Code	Title	Description
2004-08-31	MM	Patent lapsed	Owner name: SANDOZ AG